Market closedNon-fractional
Atossa Therapeutics/ATOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Ticker
ATOS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Seattle, United States
Employees
12
Website
www.atossatherapeutics.com
ATOS Metrics
BasicAdvanced
$177M
Market cap
-
P/E ratio
-$0.24
EPS
1.21
Beta
-
Dividend rate
Price and volume
Market cap
$177M
Beta
1.21
Financial strength
Current ratio
16.339
Quick ratio
15.758
Management effectiveness
Return on assets (TTM)
-18.85%
Return on equity (TTM)
-29.84%
Valuation
Price to book
2.06
Price to tangible book (TTM)
2.06
Price to free cash flow (TTM)
-9.514
Growth
Earnings per share change (TTM)
5.06%
3-year earnings per share growth (CAGR)
-30.80%
What the Analysts think about ATOS
Analyst Ratings
Majority rating from 4 analysts.
ATOS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.8M
-24.68%
Profit margin
0.00%
NaN%
ATOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.05
-$0.09
-$0.05
-
Expected
-$0.06
-$0.07
-$0.06
-$0.07
-$0.06
Surprise
33.33%
-28.57%
58.82%
-25.00%
-
ATOS News
AllArticlesVideos
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
GlobeNewsWire·5 days ago
Atossa Therapeutics names Heather Rees as CFO
Proactive Investors·3 weeks ago
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atossa Therapeutics stock?
Atossa Therapeutics (ATOS) has a market cap of $177M as of July 27, 2024.
What is the P/E ratio for Atossa Therapeutics stock?
The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of July 27, 2024.
Does Atossa Therapeutics stock pay dividends?
No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Atossa Therapeutics dividend payment date?
Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Atossa Therapeutics?
Atossa Therapeutics (ATOS) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Atossa Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.